NASDAQ · Healthcare
Invest in XTL Biopharmaceuticals stock from India
Indian and foreign residents can buy XTL Biopharmaceuticals (XTLB) shares directly through Paasa.
By Paasa · Updated
XTL Biopharmaceuticals at a glance
- Price
- $2.20-$0.21 (8.71%)
- Market cap
- $2.08M
- Day range
- $2.20 – $2.43
- P/E
- -1.01
- Dividend yield
- None
- Volume
- 1.03K
- 1 month
- -14.72%
- 6 months
- -16.35%
- YTD
- -5.17%
- 1 year
- -52.99%
- 5 years
- -86.71%
XTL Biopharmaceuticals statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $0.0 | $451.0K | $0.0 | $0.0 | $0.0 |
| Gross profit | $0.0 | $3.0K | $0.0 | −$1.0K | −$1.0K |
| Operating income | −$1.7M | −$2.2M | −$765.0K | −$880.0K | −$1.0M |
| Net income | −$7.0M | −$1.0M | −$1.8K | −$1.3M | $435.0K |
| Earnings per share | −$17.00 | −$2.40 | −$30.00 | −$4.00 | $1.28 |
| EBITDA | −$752.0K | −$930.0K | −$764.0K | −$879.0K | −$1.0M |
| Total assets | $166.0K | $8.6M | $2.4M | $4.2M | $6.6M |
| Total debt | $269.0K | $138.0K | $0.0 | $0.0 | $0.0 |
| Cash and short-term investments | $144.0K | $1.1M | $2.0M | $3.7M | $6.1M |
| Shareholders' equity | −$254.0K | $5.4M | $2.2M | $4.0M | $5.3M |
| Operating cash flow | −$1.0M | −$1.6M | −$707.0K | −$901.0K | −$1.0M |
| Free cash flow | −$1.0M | −$1.7M | −$707.0K | −$901.0K | −$1.0M |
| Capital expenditure | $0.0 | −$54.0K | $0.0 | $0.0 | $0.0 |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in USD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| VYNE Therapeutics | VYNE | $28.56 | $19.07M |
| Pasithea Therapeutics | KTTA | $0.50 | $16.68M |
| Cyclerion Therapeutics | CYCN | $23.52 | $15.73M |
| Quoin Pharmaceuticals | QNRX | $6.43 | $12.91M |
| Polyrizon | PLRZ | $10.78 | $12.07M |
| KALA BIO | KALA | $0.48 | $9.20M |
| Ensysce Biosciences | ENSC | $0.41 | $6.34M |
| Alaunos Therapeutics | TCRT | $1.09 | $2.66M |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- —
- High
- —
- Median
- —
- Consensus
- —
Ratings: 2 buy · 0 hold · 0 sell. Consensus: Buy.
Published sell-side 12-month targets in USD, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in XTL Biopharmaceuticals from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit.
Step 3
Search XTLB and buy
Find XTL Biopharmaceuticals by name or by its ticker, XTLB, and place your order. Fractional shares are available and there is no minimum trade size, so you can buy by amount instead of whole shares.
Why invest in XTL Biopharmaceuticals from India
What XTL Biopharmaceuticals does
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals operates in the Biotechnology industry within the Healthcare sector.
Hold a dollar asset
XTL Biopharmaceuticals shares are priced in US dollars, so a weaker rupee adds to what they're worth in rupees. The rupee depreciated over 85% against the dollar between 2010 and 2025.
Buy a fraction of a share
Buy by amount, not by share, and get the matching fraction of one XTL Biopharmaceuticals share. There is no minimum trade size.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy XTL Biopharmaceuticals stock from India?
Yes. Indian residents and NRIs can buy XTL Biopharmaceuticals (XTLB) shares directly through Paasa. XTL Biopharmaceuticals is listed on NASDAQ, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full XTL Biopharmaceuticals share?
No. You can buy part of one XTL Biopharmaceuticals share and add to your position over time. One share is $2.20, and you can buy whole shares or any fraction; there is no minimum trade size.
How are XTL Biopharmaceuticals dividends taxed for Indian investors?
XTL Biopharmaceuticals trades on NASDAQ but is domiciled in Israel, so any withholding on its dividends follows that country's rules rather than those of the US. What trades there is a depositary receipt over XTL Biopharmaceuticals shares rather than the ordinary share itself. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell XTL Biopharmaceuticals shares?
The US does not levy capital gains tax on shares for Indian residents. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the USD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.